Rheumatoid arthritis patients should be referred more swiftly

Dobson, Roger
May 2009
BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/9/2009, Vol. 338 Issue 7703, p1097
Academic Journal
The article reports on a consensus statement on the treatment of rheumatoid arthritis in Great Britain that was published in a 2009 issue of "Rheumatology". The authors of the statement suggested that patients with rheumatoid arthritis should be referred to a specialist rheumatology clinic as soon as the condition is first suspected, that they should be started on effective treatment as soon as possible, and that dedicated early assessment services should be developed in Great Britain for rheumatoid arthritis.


Related Articles

  • How does the Short Form 36 Health Questionnaire (SF-36) in Rheumatoid Arthritis (RA) Relate to RA Outcome Measures and SF-36 Population Values? A Cross-Sectional Study. Birrell, F. N.; Hassell, A. B.; Jones, P. W.; Dawes, P. T. // Clinical Rheumatology;May2000, Vol. 19 Issue 3, p195 

    : The aim of the study was to show that the SF-36 is a practical tool for use on outpatients with RA, to examine the relationship between the SF-36 and indices of outcome in RA, and to compare the results with population norms and other disease states. Eighty-six consecutive RA patients...

  • Editorials: Sulphasalazine in rheumatoid arthritis: an old drug revived. Neumann, V. C.; Grindulis, K. A. // Journal of the Royal Society of Medicine;Mar1984, Vol. 77 Issue 3, p169 

    The article discusses the benefits of sulphasalazine in treating rheumatoid arthritis. Sulphasalazine is an old drug which is a compound of sulphapyridine and 5-aminosalicylic acid linked by an azo bond. The benefits of salicylates in rheumatoid arthritis have an excellent effect on the...

  • Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. Kontodimopoulos, Nick; Bozios, Panagiotis; Yfantopoulos, John; Niakas, Dimitris // European Journal of Health Economics;Apr2013, Vol. 14 Issue 2, p307 

    The purpose of this methodological study was to to provide insight into the under-addressed issue of the longitudinal predictive ability of mapping models. Postintervention predicted and reported utilities were compared, and the effect of disease severity on the observed differences was...

  • RA AFTER VIOXX: WHAT NOW? Hitchens, Kathy // Drug Topics;1/10/2005, Vol. 149 Issue 1, p32 

    Treating rheumatoid arthritis (RA) is challenging enough as it is without the latest studies linking cyclooxygenase-2 inhibitors, often as used as adjunct therapy, with an increased heart risk. These studies have left many RA patients and physicians a bit apprehensive about continuous high-dose...

  • When It Comes to TREATMENT, Early is Best. Mann, Denise; Siegfried, Donna Rae // Arthritis Today;May2005, Vol. 19 Issue 3, p38 

    Focuses on the benefits of early treatment for rheumatoid arthritis (RA). Drugs used for the treatment of RA; Risk of a patient for persistent disease; Achievement by people with early RA of clinical remission.

  • Disease-modifying drugs in rheumatoid arthritis. Warburton, Louise // Update;Jun2007, Vol. 74 Issue 6, p30 

    The article presents information on the therapeutic use of disease-modifying drugs (DMARDs) in rheumatoid arthritis (RA). It is reported that early diagnosis of RA enables early therapeutic intervention with DMARDs and a much better prognosis for the patient. Recently published guidelines of the...

  • Non-drug care for RA—is the era of evidence-based practice approaching? Vlieland, T. P. M. Vliet // Rheumatology;Sep2007, Vol. 46 Issue 9, p1397 

    Non-pharmacological treatment modalities are often recommended, prescribed and used in addition to drug treatment in patients with rheumatoid arthritis (RA). This article provides a review of the literature on their effectiveness.

  • Biomarker und personalisierte Medizin. Scherer, H.U.; Burmester, G.-R.; Häupl, T. // Zeitschrift für Rheumatologie;Feb2013, Vol. 72 Issue 1, p20 

    Biomarkers form the basis for patient stratification and the development of individualized treatment strategies. As the understanding of the pathophysiological processes underlying rheumatic diseases increases, novel biomarkers will become available and established markers can be used more...

  • Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Péntek, Márta; Poór, Gyula; Wiland, Piotr; Olejárová, Martina; Brzosko, Marek; Codreanu, Catalin; Brodszky, Nóra; Gulácsi, László // European Journal of Health Economics;May2014 Supplement, Vol. 15, p35 

    Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics